News|Articles|November 16, 2026

Cretostimogene reduces recurrence risk by 68% in phase 3 PIVOT-006 trial in NMIBC

Author(s)Hannah Clarke
Listen
0:00 / 0:00

Key Takeaways

  • PIVOT-006 randomized 367 intermediate-risk NMIBC patients post-TURBT to intravesical cretostimogene versus surveillance, excluding high-risk features such as HG T1 and CIS.
  • Adjuvant cretostimogene achieved the primary endpoint, improving RFS with a 68% recurrence-risk reduction (HR 0.32; 95% CI, 0.23-0.45; P<.0001).
SHOW MORE

CG Oncology plans to submit a second biologics license application to the FDA for cretostimogene in BCG-unresponsive NMIBC by the end of March 2027

Cretostimogene grenadenorepvec, an investigational intravesical oncolytic immunotherapy, significantly improved recurrence-free survival (RFS) compared with surveillance following tumor resection in patients with intermediate-risk and high-grade Ta non-muscle-invasive bladder cancer (NMIBC), according to topline findings from the phase 3 PIVOT-006 trial (NCT06111235).1

The randomized trial met its primary end point, with cretostimogene associated with a 68% reduction in the risk of disease recurrence compared with surveillance.

“For patients with intermediate-risk and high-grade Ta NMIBC, reducing recurrence is a meaningful clinical objective because recurrence can bring additional invasive procedures and continued disease burden,” said Vijay Kasturi, MD, Chief Medical Officer of CG Oncology, in a news release on the results.1 “The significant improvement in recurrence-free survival observed in PIVOT-006 across both high-grade and low-grade patients underscores the promise of cretostimogene as an important potential new treatment option following tumor resection. These data give us the opportunity to change clinical practice and help more people remain cancer-free longer while reducing the burden of their disease.”

PIVOT-006 trial design and efficacy findings

PIVOT-006 was a phase 3, open-label, randomized, registrational study evaluating adjuvant intravesical cretostimogene following transurethral resection of bladder tumor (TURBT). The trial enrolled 367 patients across approximately 90 sites in the US and Canada. Participants were randomly assigned 1:1 to receive cretostimogene following complete tumor resection or undergo surveillance.

The study included patients with intermediate-risk NMIBC, as defined by the American Urological Association (AUA), with disease characteristics including recurrent low-grade (LG) Ta tumors within 12 months, solitary LG Ta tumors larger than 3 cm, multifocal LG Ta tumors, primary solitary high-grade (HG) Ta tumors 3 cm or smaller, and LG T1 tumors. Patients with high-risk disease, including HG T1 tumors and carcinoma in situ (CIS), were excluded.2

Patients assigned to the treatment arm received an induction course of cretostimogene followed by quarterly maintenance courses through month 13, provided they remained free of recurrence. Disease assessments included cystoscopy and urine cytology, with TURBT or biopsy when indicated. The control arm underwent surveillance following TURBT.

At the October 26, 2026, data cutoff, median follow-up was 17 months. The primary end point of RFS was met, with cretostimogene demonstrating a 68% reduction in the risk of recurrence compared with surveillance (HR, 0.32; 95% CI, 0.23 to 0.45; P < .0001).

Regarding safety, no grade 3 or higher treatment-related adverse events or treatment-related discontinuations were reported. The company characterized the overall safety findings as consistent with those observed in previous cretostimogene studies.

Next steps

The company plans to present the topline findings as a late-breaking podium presentation at the Society of Urologic Oncology Annual Meeting on December 2, 2026.

The PIVOT-006 findings are expected to support a planned second biologics license application (BLA) submission to the FDA for cretostimogene in intermediate-risk and HG Ta NMIBC. Based on FDA feedback, CG Oncology intends to expand its initial BLA submission to include patients with BCG-unresponsive HG papillary-only disease, in addition to patients with CIS with or without papillary tumors. The company now anticipates completing that submission by the end of March 2027.

“The unparalleled PIVOT-006 results represent a defining milestone for CG Oncology and position cretostimogene as the first and only therapeutic candidate to demonstrate a significant recurrence benefit in a pivotal phase 3 trial in intermediate-risk and HG Ta NMIBC. We are working expeditiously to complete our BLA filing in intermediate-risk and HG Ta NMIBC in the second quarter of 2027,” said Arthur Kuan, Chairman, President, and CEO of CG Oncology, in the news release.1 “Based on FDA feedback, we plan to broaden our initial BLA submission in BCG-unresponsive NMIBC, which was focused on patients with CIS with or without papillary tumors, to also include patients with high-grade papillary-only disease. Together, these populations represent the full range of BCG-unresponsive patients, and our goal is a label that reflects that. To incorporate the additional data, we now expect to complete the submission before the end of March 2027. All BLA-enabling manufacturing activities supporting both regulatory filings have been completed. Ultimately, this strategy reflects our commitment to meaningfully improve the lives of as many bladder cancer patients as possible.”

______

REFERENCES

1. PIVOT-006 phase 3 registrational trial demonstrates unprecedented improvement in recurrence-free survival (RFS) for intermediate-risk and high-grade Ta non-muscle invasive bladder cancer (NMIBC). News release. CG Oncology. November 16, 2026. Accessed November 16, 2026. https://ir.cgoncology.com/news-releases/news-release-details/pivot-006-phase-3-registrational-trial-demonstrates

2. A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT. ClinicalTrials.gov. Last updated July 1, 2026. Accessed November 16, 2026. https://clinicaltrials.gov/study/NCT06111235


Related to this article